Plain-English translation of NCT05098821 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Atopic Dermatitis research guide →This research study is following adults with severe atopic dermatitis (eczema) who are starting treatment with dupilumab, a medication that helps control the immune system. By analyzing blood samples collected at different time points, researchers hope to identify immune cell patterns that can predict which patients will respond best to this treatment—and which may need a different approach.
Currently, doctors cannot easily predict in advance who will benefit most from this medication. By finding specific immune cell markers before treatment starts, this study could help doctors personalize treatment plans and choose the best therapy for each patient from the beginning.
You likely qualify if…
You likely don't qualify if…
You will receive dupilumab injections as prescribed by your doctor (a loading dose followed by regular maintenance doses every two weeks). You will have blood samples taken at your first visit, then 4 weeks, 8 weeks, and 16 weeks after starting the medication. Follow-up visits happen every 3 months after that. The blood samples are coded to protect your privacy and will be analyzed to study immune cell patterns.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Germany
Charite University, Berlin, Germany
Collaborators
Sanofi, LEO Pharma
Enrollment target
~25 participants
Started
October 2019
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in August 2024.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.